Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NSPR 
InspireMD Inc (NSPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NSPR (1-star) is a SELL. SELL since 5 days. Profits (-14.70%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.64% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.80M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 2 | Beta 0.6 | 52 Weeks Range 1.99 - 3.80 | Updated Date 08/29/2025 |
52 Weeks Range 1.99 - 3.80 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.21 | Actual -0.26 |
Profitability
Profit Margin - | Operating Margin (TTM) -732.23% |
Management Effectiveness
Return on Assets (TTM) -59.42% | Return on Equity (TTM) -123.51% |
Valuation
Trailing PE - | Forward PE 11.7 | Enterprise Value 85848415 | Price to Sales(TTM) 14.41 |
Enterprise Value 85848415 | Price to Sales(TTM) 14.41 | ||
Enterprise Value to Revenue 12.15 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 41720700 | Shares Floating 28846083 |
Shares Outstanding 41720700 | Shares Floating 28846083 | ||
Percent Insiders 18.19 | Percent Institutions 32.86 |
Upturn AI SWOT
InspireMD Inc
Company Overview
History and Background
InspireMD, Inc. is a medical device company focused on the development and commercialization of proprietary MicroNet stent technology for the treatment of vascular and structural heart conditions. Founded in 2005, the company has focused on innovation in embolic protection during interventional procedures.
Core Business Areas
- Neurovascular: Develops and commercializes devices for neurovascular procedures, aiming to prevent stroke and other neurological complications. The CGuard Embolic Prevention System (EPS) is their primary neurovascular offering.
- Peripheral Vascular: Offers solutions for peripheral vascular interventions, targeting conditions like peripheral artery disease.
Leadership and Structure
The company is led by a management team with experience in medical device development and commercialization. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and clinical affairs.
Top Products and Market Share
Key Offerings
- CGuard Embolic Prevention System (EPS): A carotid stent system designed to prevent embolic events during carotid artery stenting. Market share data is not readily available, and it faces competition from companies like Boston Scientific, Medtronic, and Abbott who provide alternative carotid stenting solutions.
Market Dynamics
Industry Overview
The medical device industry, particularly the vascular intervention market, is highly competitive and characterized by technological innovation. Demand is driven by an aging population and increasing prevalence of vascular diseases.
Positioning
InspireMD aims to position itself as a leader in embolic protection during vascular procedures, differentiating itself through its MicroNet technology.
Total Addressable Market (TAM)
The total addressable market for carotid artery stenting and embolic protection devices is estimated to be in the billions of dollars globally. InspireMD's positioning within this TAM is focused on the high-risk patient segment requiring advanced embolic protection.
Upturn SWOT Analysis
Strengths
- Proprietary MicroNet technology
- Focus on embolic protection
- Potential for significant clinical benefit in high-risk patients
Weaknesses
- Limited financial resources
- Small market share
- Dependence on single product line
Opportunities
- Expansion into new geographic markets
- Development of new applications for MicroNet technology
- Partnerships with larger medical device companies
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BSX
- MDT
- ABT
Competitive Landscape
InspireMD faces significant competition from larger, more established medical device companies. Its competitive advantage lies in its proprietary MicroNet technology, but it must overcome challenges related to market access and reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been challenged with high volatility.
Future Projections: Future projections are contingent on successful commercialization of products and market adoption. Analyst estimates vary.
Recent Initiatives: Recent initiatives include strategic partnerships, product development, and sales expansion efforts.
Summary
InspireMD is a small medical device company with a unique technology in the vascular intervention space. Its MicroNet technology offers potential benefits, but it faces significant challenges. Success depends on its ability to secure funding, expand its market share, and navigate regulatory hurdles. Its a risky play, but could have good gains with the right investment. The company needs to be careful around it's current competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InspireMD Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2011-04-12 | President, CEO & Director Mr. Marvin L. Slosman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 66 | Website https://www.inspiremd.com |
Full time employees 66 | Website https://www.inspiremd.com | ||
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.